Tumor growth and metastasis are angiogenesis-dependent. The possibility of inhibiting tumor growth by interfering with the formation of new vessels has recently raised considerable interest. We previously reported that it is possible to inhibit primary tumor growth and metastasis in a transgenic model of spontaneous breast tumor, which shows many similarities to its human counterpart (including ability to metastasize) by intratumoral administration of a DNA conKeywords: gene therapy; breast adenocarcinoma; metastasis; transgenic mice; anti-angiogenesis; liposomes
It is now widely recognized that the development of new blood vessels (angiogenesis) is necessary to sustain tumor growth, invasion and metastasis. At some point during tumor growth, cancer cells acquire the ability to activate the quiescent vasculature to produce new blood vessels via a so-called 'angiogenic switch'. 1, 2 Although the need for recruiting new blood vessels to the tumor has been know for more than two decades, the possibility of treating malignancies by acting on their vasculature has become popular only since the isolation of endogenous angiogenesis inhibitors, which dramatically affect cancer growth in experimental murine systems. Highly promising results on experimental tumors in rodents using these inhibitors as purified proteins as well as transduced genes, alone or in combination with traditional therapies have been reported. [3] [4] [5] [6] [7] The establishment of a dormancy status, which in some cases persists even after the suspension of therapy, has been obtained with these gene products, 5 and this, together with the absence of drug resistance, 8 raised the possibility that the anti-angiogenic effects could be useful in the treatment of human tumors.
The achievement of the inhibition of local tumor growth is the usual end-point of these therapeutical attempts, but in humans it is the metastatic spread that is responsible for the majority of cancer-related deaths. Therefore, to be really useful in the human context, any new approach must be evaluated in its ability to interfere struct carrying the murine angiostatin cDNA driven by liposomes. Here we report that it is also possible to achieve this goal by a systemic (intraperitoneal) delivery of therapeutic DNA constructs carrying genes coding for mouse and human anti-angiogenic factors which include angiostatin, endostatin and TIMP-2. These findings may be relevant to the design of therapeutic interventions in humans. Gene Therapy (2001) 8, 67-70.
with tumor cell invasion and metastasis, a therapeutical target which is rarely, if ever, investigated at the experimental level. Unfortunately, most of the results in experimental oncology have been obtained on transplantable tumors which are usually generated by inoculating highly malignant cultured cells, which rapidly grow in the site of injection and become the target for therapeutic intervention. As we have previously pointed out, although this approach has greatly benefited basic investigation in tumor biology, it is now being recognized that it is artificial to a great extent and it is not representative of what can be done at present in humans. Therefore, we have extensively validated a transgenic mouse model of breast carcinoma which has many similarities with its human counterpart, including the ability to give rise to distant metastases, allowing us to investigate the efficacy of novel gene therapy-based approaches on metastatic growth. [9] [10] [11] [12] [13] As previously shown, in this model, based on MMTV-neu transgenic mice, breast tumors grow very reproducibly in 100% of the transgenic females, arise relatively slowly in an immunocompetent host and involve the neu oncogene, which is known to play a role in human breast cancer. In addition, these tumors give rise to distant metastases in the 4th or 5th month of age, which are easily detected by histopathological examination. 13 So far, the transgenic model has been exploited only by Hanahan's and Folkman's groups, although the tumor investigated by them is rare in humans and is related to the SV40 T antigen, which is not directly involved in human pathology. 2, 14 In the present work we have investigated the systemic effect of liposome-mediated anti-angiogenic gene administration on our transgenic model. We have previously demonstrated that a local (intratumoral) administration of a construct carrying angiostatin cDNA was able to inhibit primary tumor growth and metastasis. In particular, the strong effect obtained on metastasis, suggests that this approach could be applied to the prophylactic therapy of breast cancer after removal of primary tumor. 13 In the present study, we used the same liposome-based approach (with a different delivery route) used in our previous experiments, as DNA-liposome complexes are easily prepared, have already been used in gene therapy clinical trials as well as in cosmetics, show little toxicity when administered locally or even parenterally, can be repeatedly administered, do not raise immunological responses, do not show any danger of recombination with endogenous viral sequences and can also be manipulated by physicians in small peripheral hospitals. 15 The latter consideration could be relevant, should the angiogenesis inhibition approach become a widely used tool for cancer therapy.
In addition to the choice of the experimental model, to tackle this problem rationally, gene products which play a role in the genesis of distant metastases must be identified and their role must be elucidated. Metastasis growth is thought to be dependent on expression of genes involved in angiogenesis, but additional genes are likely to be required. Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases which have a role in degradation of the extracellular matrix components, 16, 17 as well as angiogenesis [18] [19] [20] [21] and have been involved in facilitating tumor cell invasion and metastasis. These proteins share a common domain with a family of proteins which play an opposite role, the tissue inhibitors of metalloproteinases (TIMPs), which inhibit MMPs by forming tight-binding, non-covalent association with the active site of MMPs. 22 The design of therapies addressed to interfere with this action (by over-expressing TIMP genes) may be of help in the control of metastatic disease. 23 Although the relationship between invasion, matrix degradation, morphogenesis and new vessel formation is not completely clear, it is likely that inhibition of different steps of these processes could have summatory or even synergistic effects.
With these considerations in mind, we investigated the possibility of systemically delivering inhibitory genes via nonviral vectors. We chose the systemic route of administration for several reasons. First, it should result in transformation of normal cells which are less prone to undergo genetic loss than tumor cells. Second, in some situations in human pathology, such as adjuvant therapy, no detectable tumor is present, and finally, this protocol is very easy to implement.
In the present work, liposomes carrying DNAs coding for anti-angiogenic factors (murine angiostatin, human angiostatin and human endostatin) and the MMPs inhibitor human TIMP2 under the control of various promoters were injected intraperitoneally in MMTVneu females in order to evaluate their efficacy on the inhibition of primary tumor growth and metastasis (see Figure 1) .
Intraperitoneal treatments started at 2 months of age and were performed weekly until the mice reached 5 months of age. In our transgenic model, tumors can be detected by pathological examination at 1 month of age and become clinically detectable at 9-10 weeks of age, growing rapidly and reaching the size of about 1 g at about 5 months of age. All the four liposome-complexed constructs were inoculated separately in groups of four mice, except the MMTV-Ang construct which was injected in eight animals. An additional group of eight mice was not treated (controls), while a further four additional mice were injected with a construct containing a grossly deranged, non-functional endostatin gene. 13 All the mice were then killed and a complete necropsy was performed. PCR performed on tumors and tissues from angiostatin and endostatin-treated mice showed that at the moment of death the lipofected DNA was present in tissues from treated mice, but not from control mice. At least one tissue analyzed was positive for every mouse, although the number and type of positive tissues varied, with the kidney being the most frequently positive organ (see Table 1 ). In this regard, it is known that various factors can affect liposome distribution in vivo, including dif- DNA was extracted according to standard procedures from liver, kidney, spleen, lung and two tumors from a total of 16 treated and eight untreated mice, and subjected to PCR analysis with specific primers (available upon request). Positive and negative controls were included in the PCR reactions. Positive controls were performed on 10 ng of the plasmids used for the various treatments. The percentage of integration of injected DNAs into the various tissues was calculated as the ratio between PCR positive samples and the total number of samples examined.
ferences among species, liposome formulations and route of administration. 15 The effect of therapy with human and murine genes on local tumor growth inhibition was evaluated by comparing the tumor weight in all the treatment groups, as done in our previous work. [9] [10] [11] [12] [13] While in 5-month-old control animal tumors reached the size of about 1 g, in all the treated groups we observed an inhibition of tumor growth with all the constructs. The reduction of tumor weight was about 40% in the TIMP2-treated group, 50% in the MMTVang and BSHend and about 65% in the BSHang-treated groups compared with the control one (see Figure 2) . The reductions obtained in all these groups were statistically significant when compared with controls. As expected for the administration route used, no difference between tumors of the two sides was detected.
The effect on metastatic dissemination, either direct or indirect, was evaluated by careful examination of lungs from treated and control mice (see Ref. 13 for details) . Lung metastases are a consistent feature of the MMTVneu transgenic mice. To determine whether the delay in local tumor growth also affects the ability of cancer cells to spread to distant sites, we performed a careful examination of lungs in the 5-month-old treated and control mice, an age at which approximately 80% of MMTV-neu mice bear lung metastases. 13 As shown in Table 2 , no lung metastases were detected in the eight mice treated with MMTVang construct, and these data are similar to our previous results obtained by intratumoral administration of the same liposome-DNA complex. 13 Only two very small metastases were present in one of the four mice injected with the TIMP2 construct. Likewise, only one out of four mice treated with the human angiostatin construct showed lung metastases, whereas the human endostatin construct seemed to be less effective in terms of reduction of the appearance of lung metastases, although their size was smaller than that of the controls. This could represent a species-specific effect. The figures obtained with the nonfunctional endostatin DNA construct used as control did not differ from the control group. 0  6368  12  0  0  0  6357  13  0  0  0  MMTVang  6267  13  0  0  0  6277  14  0  0  0  6282  19  0  0  0  6283  16  0  0  0  6308  14  0  0  0  6314  14  0  0  0  6312  14  0  0  0  6309  14  0  0  0  pTimp2  6646  14  0  0  0  6651  13  0  0  0  6652  15  2  0  0  6671  12  0  0  0 Metastases were carefully evaluated in all the histological sections of the lungs in order to determine the total number and size: they were counted and scored as small (Ͻ10 cells), intermediate (10-100 cells) , and large (Ͼ100 cells).
Taken together, these results show that angiostatin delivered with this protocol delays both primary tumor growth and metastatic dissemination with murine angiostatin being more effective than the human one in terms of inhibition of the appearance of metastases. Although we did not perform vessel density analysis in this series, a decrease in vessel density has been found in our previous studies in which angiostatin cDNA was injected intratumorally in the same mouse model. 13 While most previously reported studies with angiostatin and endostatin were performed using purified proteins, the findings presented here have been obtained with a gene transfer approach. Very recently, intramuscularly administered endostatin cDNA has shown a systemic effect against transplantable tumors, 24 and our previous work demonstrated both the local and systemic effect of angiostatin gene therapy administered intratumorally into spontaneous murine breast adenocarcinomas. These findings suggest that angiogenesis inhibitors delivered by gene transfer approaches could represent an alternative to the administration of the purified protein.
The present report suggests that systemic gene therapy with human and murine anti-angiogenic genes, including TIMP2 whose mechanism of action could differ from that of angiostatin and endostatin, can be effective on both local and metastatic tumor growth. Our system allows the evaluation in a natural setting of the effect of angiogenesis on the metastasis process, which is the leading cause of mortality in human tumoral pathology. The association of angiostatin and/or endostatin with anti-MMP gene therapy may improve the efficacy of the approach. This is a very promising finding which strengthens the putative clinical usefulness of anti-angiogenic treatment in humans. This approach could be also useful as an adjuvant treatment after surgery, possibly in combination with conventional treatments. In this regard, our model could be a useful tool to test all these combinations.
